5 Fastest Growing Tech Penny Stocks to Buy

3. Ovid Therapeutics Inc. (NASDAQ:OVID)

On July 8, 2026, Ovid Therapeutics Inc. (NASDAQ:OVID) announced several strategic appointments. Kevin Norrett will join Ovid as chief business officer to lead business and corporate development functions, as well as strategic partnerships. Most recently, Norrett served as chief business officer at Soleno Therapeutics.

Ovid also promoted Charles Carter to CFO, where Carter will lead business and financial operations. Carter succeeds Jeffrey Rona, who will remain a long-term advisor to the company through 2027. Victoria Fort was promoted to chief strategy officer, leading enterprise strategy, investor relations, and operational growth initiatives.

In May, Ovid Therapeutics reported Q1 EPS of (12c), compared with the consensus of (11c). CEO Meg Alexander said the first quarter reflected “focused execution” and continued progress across the company’s pipeline of small molecule medicines for intractable brain conditions. Alexander said development programs remain on track, the clinical organization has expanded, and the company expects to be well capitalized into 2029.

Ovid Therapeutics Inc. (NASDAQ:OVID) develops small-molecule medicines for brain disorders, including epilepsies and seizure-related neurological disorders in the United States.